Skip to main content

Lung Cancer HELPLine 844-360-5864

LUNGevity.org

Navigating KRAS

Lung Cancer HELPLine 844-360-5864

Other gateways  

Main navigation

  • About KRAS-Positive Lung Cancer
  • Find a Specialist
  • Learn About Clinical Trials
  • Find Your Community
  • News and Events
  • Video Library

Main navigation

  • Close
  • Lungevity Gateway Hub
  • KRAS
    • About KRAS-Positive Lung Cancer
    • Find a Specialist
    • Learn About Clinical Trials
    • Find Your Community
    • News and Events
    • Video Library
  • NSCLC
    • About Non-Small Cell Lung Cancer
    • Find a Specialist
    • Learn About Clinical Trials
    • Find Your Community
    • News and Events
    • Video Library
  • ALK
    • About ALK-positive Lung Cancer
    • Find a Specialist
    • Learn About Clinical Trials
    • Find Your Community
    • News and Events
    • Video Library
  • EGFR
    • About EGFR-Positive Lung Cancer
    • Find a Specialist
    • Learn About Clinical Trials
    • Find Your Community
    • News and Events
    • Video Library
  • Rare Mutations
    • About Rare Mutations and Fusions in NSCLC
    • Find a Specialist
    • Learn About Clinical Trials
    • Find Your Community
    • News and Events
    • Video Library

Radon and Lung Cancer: Current Trends and Future Perspectives

Submitted by Anonymous on Mon, 06/27/2022 - 11:55
  • Read more about Radon and Lung Cancer: Current Trends and Future Perspectives

to mutations in

KRAS

and

TP53

. McDonald et al. found a 31% of

TP53

mutations and a 39% of

KRAS

mutations in 52 lung cancer cases

Cancer treatment and survivorship statistics, 2022

Submitted by Anonymous on Thu, 06/23/2022 - 14:04
  • Read more about Cancer treatment and survivorship statistics, 2022

have metastatic colorectal cancer have tumors with specific molecular profiles (eg, KRAS/NRAS/BRAF wild-type tumors or those with BRAF V600E

Adagrasib Promising in KRASG12C-Mutated NSCLC

Submitted by Anonymous on Thu, 06/23/2022 - 13:25
  • Read more about Adagrasib Promising in KRASG12C-Mutated NSCLC

KRAS

G12C

inhibitor adagrasib shows promising efficacy in pretreated patients with advanced non-small cell lung cancer harboring a

KRAS

Machine learning‐based gene alteration prediction model for primary lung cancer using cytologic images

Submitted by Anonymous on Tue, 06/21/2022 - 02:03
  • Read more about Machine learning‐based gene alteration prediction model for primary lung cancer using cytologic images

: anaplastic lymphoma kinase (ALK)-fusion, epidermal growth factor receptor (EGFR), or Kirsten rat sarcoma viral oncogene homologue (KRAS)

A Molecular Revolution Is Underway in Thoracic Oncology

Submitted by Anonymous on Mon, 06/20/2022 - 14:57
  • Read more about A Molecular Revolution Is Underway in Thoracic Oncology

Targetable alterations including

BRAF

V600E,

EGFR

exon 20 insertions,

KRAS

G12C mutations,

MET

exon 14 alterations,

NTRK

and

RET

A full-on attack is launched on cancer and HIV

Submitted by Anonymous on Mon, 06/20/2022 - 12:38
  • Read more about A full-on attack is launched on cancer and HIV

version of a gene known as KRAS is present in as many as 90 percent of pancreatic cancer cases.

“The mutant form of the KRAS gene is one of

BMS, Mi­rati fund new Stand Up To Can­cer re­search teams, adding to list of phar­ma part­ner­ships

Submitted by Anonymous on Sat, 06/11/2022 - 08:46
  • Read more about BMS, Mi­rati fund new Stand Up To Can­cer re­search teams, adding to list of phar­ma part­ner­ships

Myers Squibb on lung cancer disparities and Mirati Therapeutics on KRAS cancers.

The new additions augment Stand Up To Cancer’s pharma

A Potential GSK Game Changer And An MRNA Cancer Vaccine: Highlights From The 2022 ASCO Conference

Submitted by Anonymous on Fri, 06/10/2022 - 17:45
  • Read more about A Potential GSK Game Changer And An MRNA Cancer Vaccine: Highlights From The 2022 ASCO Conference

the Phase 1b study of Mirati’s cancer therapy adagrasib. The patients in the study had Non-small Cell Lung Cancer that had spread to the

KRAS-Mutant NSCLC: Has the 'Undruggable' Cancer Finally Met Its Match?

Submitted by Anonymous on Fri, 06/10/2022 - 10:00
  • Read more about KRAS-Mutant NSCLC: Has the 'Undruggable' Cancer Finally Met Its Match?

from the

KRAS Kickers

patient advocacy subgroup: Can we kick cancer's KRAS harder? Will we see improved efficacy with novel KRAS

G12C

Subscribe to Newsfeed

You are about to leave the Patient Gateway

You’re one click away from learning about one of our most valued sponsors. Read about how they’re making a difference in patients’ lives.

ProceedCancel

LUNGevity Foundation

CHICAGO OFFICE

228 S. Wabash, Suite 700
Chicago, IL 60604
Phone: 312-407-6100
info@LUNGevity.org

BETHESDA OFFICE

6917 Arlington Road, Suite 352
Bethesda, MD 20814
Phone: 240-454-3100

MAILING ADDRESS

PO Box 754
Chicago, IL 60690

Privacy policy | Contact us

This website is not intended to, and does not, provide medical advice, professional diagnosis, opinion, treatment, or services. Medical information provided on this site is for informational and educational purposes only. After reading content from this website, you are encouraged to review the information carefully with your physician.

© 2021 LUNGevity Foundation. All rights reserved.

Charity Navigator Four-Star Charity
Registered charity
guidestar platinum transparency 2021
Copyright © 2022 LUNGevity Foundation. All rights reserved.